ABSTRACT

First-line panitumumab and FOLFIRI was associated with favorable efficacy in patients with RAS WT mCRC and was well tolerated.

A total of 47 patients were enrolled. The median age was 60 years old (range of 35-78). Twenty-seven patients were male, and 20 were female. The median follow-up was 16.4 months, and the median PFS was 11.6 months. Median OS was 26 months in patients with KRAS wildtype mCRC. In wild-type KRAS and NRAS, mCRC patients’ median PFS was 14 months, median OS was 27 months, 90.7% for six-month OS, 82.6% for one-year OS, 82.6% for two-year OS, and 66.1% for three-year OS. The most frequent grade 1/2 toxicities were diarrhea (34.1%), acne-like rash (46.7%), and neutropenia (35.1%). The most frequent grade 3/4 toxicities were diarrhea (7.3%), acne-like rash (6.7%), and neutropenia (11.1%).

In our retrospective study, patients with RAS wild-type mCRC were enrolled into the medical oncology department in Okmeydanı Training and Research Hospital, İstanbul, between April 2014 and September 2016.

FOLFIRI is widely used in clinical practice for mCRC patients. Panitumumab is used in patients with KRAS wild-type mCRC.This study investigated the efficacy and safety of first-line panitumumab plus FOLFIRI for patients with KRAS wild-type mCRC.